19-01-24_PRIORITY_RGB_logo_v1.png

Supporting and rewarding unique and pioneering research initiatives to address the unmet needs of patients with rare genetic disorders.

The PTC Innovative Research Funding program, PRIORITY, is a global program designed to provide funding, through duly eligible research entities, to biomedical researchers and clinicians who are interested in developing unique and collaborative research programs that will improve clinical practice for patients with rare genetic disorders. The 2019 PRIORITY program will focus on Duchenne muscular dystrophy (DMD) and invites funding proposals for innovative research projects that will help improve rates of DMD screening in infants and facilitate earlier diagnosis of this progressive muscle-wasting disease.

Funds are awarded to the eligible research entities via a competitive process in which all entries are reviewed by an independent external Review Committee whose members have significant interest and expertise in rare genetic disorders and previous experience with funding initiatives. Funding will be awarded for one year.

By selecting Confirm, you are leaving the PTC Therapeutics U.S. website. This external link is provided for your convenience. Please note that external links or web sites may not be controlled by PTC Therapeutics, and thus not subject to our Privacy policy and Terms of use.

Thank you for visiting our site.
Cancel Confirm
This site uses cookies to store information on your computer.
Cancel Continue